β Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (464) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ§© Revenue Segmentation by Product
Switch to Location
Fiscal year | Segment | Value |
---|---|---|
2024 | Sotyktu | 246M |
2024 | Breyanzi | 747M |
2024 | Sprycel | 1.29B |
2024 | Eliquis | 13.33B |
2024 | Pomalyst/Imnovid | 3.55B |
2024 | Zeposia | 566M |
2024 | Augtyro | 38M |
2024 | Abecma | 406M |
2024 | Reblozyl | 1.77B |

π° Explore more revenue segmentation data for Bristol Myers Squibb!
Sign up for free or log inβοΈ Sign up to get "The Checklist Value Investor β A Smarter Way to Pick Stocks" for free